Indications
Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza.
Composition
- Active substance
- darunavir, cobicistat, emtricitabine, tenofovir alafenamide
- International name (INN)
- darunavir;cobicistat;emtricitabine;tenofovir alafenamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Symtuza
- Active substance
- darunavir, cobicistat, emtricitabine, tenofovir alafenamide
- ATC code
- J05AR22
- Therapeutic area